(Sanofi)
Sanofi doubled down on its original 2018 pact with Translate Bio last year as the pair teamed up for an mRNA approach to COVID vaccines, and today the two announced they are starting clinical trials using the tech.
The phase 1/2 trial, which was originally guided for the fourth quarter 2020 but has slid into Q1, will look to enroll 415 participants using the mRNA vaccine MRT5500, with interim results expected in the third quarter. The trial is set up to assess safety, immune response and reactogenicity, after preclinical data showed “high neutralizing antibody levels.”
Those in the test will either get one dose of MRT5500, or two doses 21 days apart. In all, three different dose levels will be investigated (15µg, 45µg or 135µg). It did not give a breakdown of the percentage of age, gender or race of the trial, simply saying all participants will be over 18 years old.